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ABSTRACT 
 
Background:  Genetic variation in FOXO3 (tagged by rs12212067) has been 
associated with a milder course of rheumatoid arthritis (RA) and shown to limit 
monocyte-driven inflammation through a TGFβ1-dependent pathway. This genetic 
association, however, has not been consistently observed in other RA cohorts. We 
sought to clarify the contribution of FOXO3 to prognosis in RA by combining detailed 
analysis of non-radiographic disease severity measures with an in vivo model of 
arthritis. 
Methods: Collagen-induced arthritis, the most commonly used mouse model of RA, 
was used to assess how Foxo3 contributes to arthritis severity. Using clinical, 
serological and biochemical methods, the arthritis that developed in mice carrying a 
loss-of-function mutation in Foxo3 was compared with that which occurred in 
littermate controls. The association of rs12212067 with non-radiographic measures 
of RA severity, including CRP, Swollen Joint Count, Tender Joint Count, DAS28 and 
the HAQ score were modelled longitudinally in a large prospective cohort of early RA 
patients.  
Results: Loss of Foxo3 function resulted in more severe arthritis in vivo (both 
clinically and histologically) and was associated with higher titres of anti-collagen 
antibodies and IL-6 in blood. Similarly, rs12212067 (a SNP that increases FOXO3 
transcription) was associated with reduced inflammation – both biochemically and 
clinically – and with lower RA activity scores. 
Conclusions: Consistent with its known role in restraining inflammatory responses, 
FOXO3 limits the severity of in vivo arthritis and, through genetic variation that 
increases its transcription, is associated with reduced inflammation and disease 
activity in RA patients – effects that would lead to lesser radiographic damage. 
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INTRODUCTION 
Like most autoimmune and inflammatory conditions, the course of rheumatoid 
arthritis (RA) is unpredictable and highly variable between patients. While current 
guidelines advocate early and aggressive treatment for all patients to avoid 
irreversible joint damage and disability, this strategy will undoubtedly result in the 
overtreatment of patients with mild disease or those in whom the disease would have 
spontaneously entered remission. Accordingly, such patients are currently exposed 
to the risks and side-effects of unnecessary immunosuppression. To overcome this 
limitation, a personalised management strategy would be necessary, which in turn 
would rely on having a reliable method of predicting disease outcome. Currently, 
however, the predictive value of clinical or serological markers is insufficient to guide 
treatment decisions, and accordingly there is a clear and well-recognised need for 
predictive biomarkers.  
Genetics has been shown to play an important role in the development of RA 
through a series of large genome-wide association studies,[1-3] but its potential role 
in determining disease course following diagnosis has been less rigorously studied – 
even though radiographic outcome has been proposed to be partially genetically 
determined.[4] Indeed, while many studies have reported genetic associations with 
outcome, virtually none of these outside the HLA reach genome-wide significance, 
nor have they always been replicated.[5-9] We previously demonstrated that a SNP 
in FOXO3A (rs12212067: T>G) was associated with prognosis in several TNFα-
driven diseases and that this variant led to altered production of pro- and anti-
inflammatory cytokines by monocytes through a TGFβ1-dependent pathway [10]. In 
RA specifically, we showed that minor allele carriage at rs12212067 – which reduced 
TNFα, IL-6, IL-1β and IL-8 production and increased IL-10 production – was 
associated with a milder course of disease (i.e. less joint damage over time) in large 
and well phenotyped cohorts of patients with early disease. Since that report, which 
also demonstrated that rs12212067 was associated with outcome in Crohn's disease 
and malaria, several smaller studies have attempted to replicate these associations. 
In Crohn's disease[11] and malaria,[12] the reported associations have been 
independently replicated, although in RA a meta-analysis of five smaller cohorts from 
the US and Europe failed to detect the same association signal.[13] This situation is 
not unusual, and in fact is similar to that which occurred in the early GWAS era when 
some of the first associations – many of which have since been replicated several 
times – were initially questioned by negative follow-up studies in small and 
consequently underpowered cohorts.[14-16]  
Here, we sought to better understand what contribution FOXO3 might make to the 
clinical outcome of RA. To do this we first investigated whether a role for FOXO3 in 
altering arthritis severity was biologically plausible by examining the contribution of 
FOXO3 to the severity of immune-mediated arthritis in vivo. We then chose to 
examine a broader range of arthritis severity markers in a large cohort of patients 
with early RA and inflammatory polyarthritis to determine whether other associations 
might be present that would support (or indeed refute) the association of rs12212067 





To study the role of FOXO3 in immune-mediated arthritis in vivo, we used the 
collagen-induced arthritis mouse model – the most commonly used animal model of 
RA – in which arthritis is induced by immunisation with emulsified Type II Collagen in 
Complete Freund's Adjuvant (50 µl, 4 mg/ml, intradermal). We compared the severity 
of the resulting arthritis in C57BL/6 mice harbouring a missense mutation in the 
highly conserved Forkhead DNA-binding domain that abrogates the function of 
Foxo3 (Foxo3a MommeR1/MommeR1 mice; from here termed Foxo3a-/-),[17] with that 
which developed in heterozygous (Foxo3a+/-) and wild-type (Foxo3a+/+) littermates 
(all 8 weeks old). Arthritis severity was assessed using a standard scoring 
system[18] and serum anti-collagen antibodies (Chondrex), IL-6 and TNFα levels 
(R&D Systems) were assessed at day 14 by ELISA. All experiments were performed 
according to the regulations of the UK Home Office Scientific Procedures Act 
(1986).  
 
Patient cohorts and genotyping 
To further investigate the relationship between rs12212067 (a non-coding SNP 
within FOXO3) and severity in RA, we used the Norfolk Arthritis Register (NOAR), a 
primary care-based inception cohort of 4293 patients with early inflammatory 
polyarthritis (IP) who were followed prospectively from disease onset for up to 20 
years[19] (Supplementary Table 1). IP patients who satisfied the 1987 ACR criteria – 
applied cumulatively over the first 5 years of follow-up – were called RA patients (n = 
2537 Supplementary Table 1). Where available, we analysed the association of 
genotype at rs12212067 with a range of RA severity indices, including (1) 
radiographic measures (Larsen score,[20] modified Larsen score and presence of 
erosions – defined as a cortical break ≥2mm), (2) biological measures (C-reactive 
protein [CRP]), (3) patient-reported outcomes (Health Assessment Questionnaire 
[HAQ] score) and (4) disease activity scores: Swollen Joint Count (SJC), Tender 
Joint Count (TJC) and Disease Activity Score based on 28 joints (DAS28) - 
calculated using 3 variables (SJC, TJC and CRP).  Genotyping of rs12212067 was 
performed on a custom-designed genotyping chip (Illumina Immunochip) or using 
Sequenom MassArray technology. Quality control procedures for ImmunoChip data 
were as described in the original report.[2] Ethical approval for the NOAR study was 




In order to maximize power for the studies of RA or IP outcome, we incorporated 
multiple records per patient over time and considered all measures of disease 
outcome (or activity) as longitudinal continuous variables. All analyses were adjusted 
for intra-individual correlation, and a dominant model of association was used (in part 
due to the low frequency of minor allele homozygotes). To provide a positive control, 
we also analysed the shared epitope (SE), a five amino acid sequence motif in the 
HLA-DRβ chain that is known to be associated with a variety of measures of severe 
rheumatoid arthritis, using the same method. Presence or absence of the SE was 
determined experimentally using the reverse dot-blot method as described 
previously.[21] We used Generalized Linear Latent and Mixed Modelling (GLLAMM) 
for measures of radiographic outcome,[22] zero-inflated negative binomial regression 
(ZINB) for CRP,[23] and quantile (median) regression for the HAQ score, SJC, TJC 
and DAS28. More details are provided in Supplementary methods. Because the 
directions of effect of the shared epitope and the FOXO3A SNP are already known, 
one-tailed p-values are reported, as in the original study [10]. Adjustment for multiple 
testing and treatment strategies was performed where indicated. Treatment was 
integrated in the model as a time-dependent dummy variable for the presence of 
treatment with any disease modifying anti-rheumatic drug (DMARD) at every follow-
up. The proportion of the variance of a specific trait explained by the FOXO3A SNP 
was calculated as follows: the model was run with and without the SNP; for each 
model, the correlation coefficient between the observed and predicted values was 
calculated; the difference between the squares of the correlation coefficients was 
used to quantify the proportion of the variance explained by the SNP. These 
analyses were performed using Stata version 11 / 13 software (Copyright 1985-2011 
StataCorp LP, Texas, USA). 
In the collagen-induced arthritis experiments, comparison of the arthritis score 
between Foxo3-/-, Foxo3+/- and Foxo3+/+ was performed using a two way analysis 
of variance (ANOVA) and comparison of biochemical or serological parameters 
between genotypes was performed using a Wilcoxon matched pairs signed-rank 
test. One tailed p values are presented in view of the specific hypothesis being 
tested. These analyses were performed using GraphPad Prism v6.04 (GraphPad 





To investigate how altered FOXO3 function might influence the course of 
autoimmune arthritis in vivo, we first assessed the severity of collagen-induced 
arthritis in mice carrying a missense mutations in the highly conserved Forkhead 
DNA-binding domain of Foxo3, known to abrogate its function. We showed that 
carriage of the Foxo3 null allele was associated with a more severe arthritis. This 
was apparent from both the significantly higher arthritis scores (Figure 1A) and from 
joint histology, which demonstrated increased synovial expansion and cellularity and 
tissue oedema (Figure 1B). In addition to assessing the clinical severity of arthritis, 
we also sought to compare the titres of anti-collagen antibodies that were formed, as 
this enables a more direct evaluation of the immune response against type II 
collagen. These antibodies are also known to target epitopes within type II collagen 
that are shared by rheumatoid arthritis antibodies.[24] We demonstrated that higher 
levels of anti-collagen antibodies were present in mice with impaired or abrogated 
Foxo3 function (Figure 1C). We also assessed the production of IL-6 and TNFα at 
day 14, pro-inflammatory cytokines that are known to be important in the 
pathogenesis of CIA, and observed a non-significant trend to higher IL-6 levels in 
Foxo3-/- mice compared to either wild type or heterozygous littermates (P = 0.06, 
Figure 1D). Serum TNFα was not detectable at this time point (data not shown). 
In light of these results, and our previous work that demonstrated an association 
between genotype at rs12212067 and the radiographic course of RA, we elected to 
examine other indices of disease severity in a large prospectively collected cohort of 
early RA patients. First we considered other radiographic measures as it has 
recently been suggested that the number of eroded joints may constitute a more 
accurate measure of joint damage [25]. We confirmed that irrespective of the 
measure used, carriage of the minor allele at rs12212067 was associated with lower 
radiographic damage over time (i.e. lower Larsen score, lower modified Larsen score 
and fewer erosions, Table 1). In other words, patients with a milder disease course 
were more likely to carry the minor allele of rs12212067 than patients with a more 
severe disease course (the average minor allele frequency of rs12212067 in NOAR 
is 9.6%). The effect of FOXO3A rs12212067 on the Larsen score remained 
significant after adjustment for treatment (effect size equal to a reduction of 1.50 
Larsen units for the carriage of the G allele, p-value = 0.009) and was independent of 
the SE in a bivariate analysis (p-value = 0.002; Table 1). However, although this 
association was significant, the proportion of the variance of the Larsen score 
explained by the carriage of rs12212067 was low (0.07%). 
Given these data, and the TGFβ1-driven inflammatory pathway that FOXO3 has 
been shown to regulate [10], we postulated that the effect of FOXO3A on 
radiographic outcome might be mediated by a reduction of inflammation, and not by 
a direct effect on the bone, as has been suggested for other genetic markers of RA 
severity.[5] We therefore examined the entire NOAR cohort to determine whether 
there was an association between rs12212067 genotype and non-radiographic 
measures of inflammation, disease activity or outcome (including CRP, SJC, TJC, 
the HAQ score and DAS28). Data availability and the frequency and duration of 
follow-up for these different measures varied and are shown in Supplementary Table 
2. We observed significant associations of rs12212067 genotype with DAS28, SJC 
and CRP and a nominally significant association with HAQ score (p = 0.013, 
although the stringent bootstrap correction for inter-individual correlation meant that 
the corrected P value was 0.11). Notably, there was also a consistent direction of 
effect across all of the variables, with minor allele carriage at rs12212067 generally 
associating with indices of milder disease, and with effect sizes that were of a 
comparable magnitude to those that were associated with the SE (Tables 1 and 2). 
However, the proportion of the phenotypic variance explained by the carriage of 
rs12212067 remained low for non-radiographic measures of disease outcome (the 
proportion of the variance of DAS28 explained by the SNP only was 0.09%).  
The anticyclic citrullinated peptide (anti-CCP) antibody status is a strong and well 
established predictor of disease severity [33] and the effect of the SE on RA severity 
is mainly mediated by anti-CCP [22, 34]. In order to investigate the influence of anti-
CCP status on the association of FOXO3A rs12212067, we adjusted the effect of 
rs12212067 for anti-CCP status and also performed a stratification analysis by anti-
CCP status (Table 3). Although the effect of the SE on disease severity and activity 
disappeared completely after adjustment or stratification, the effect of rs12212067 on 
Larsen score or DAS28 remained significant irrespective of anti-CCP status (the 
effect size adjusted for anti-CCP was equal to a reduction of 1.26 Larsen units for 
the carriage of the G allele (95% confidence interval: -2.49; -0.03), p-value = 0.023; 
and the OR for DAS28 was equal to 0.78 (95% confidence interval: 0.67;0.90), p-






Table 1. Association of FOXO3A and the shared epitope with radiological 
measures of disease outcome  
Modified Larsen score: obtained by recalculating the Larsen score using the 
presence of joint space narrowing (in the absence of any other modification) as “0” 
instead of “1”, in order to reduce potential misclassification due osteoarthritis.  
Effect size refers to change in Larsen score units or numbers of erosive joints 
respectively. 




Shared epitope FOXO3A (rs12212067) 
 
Effect size (95% CI) P value Effect size (95% CI) P value 
Larsen score 
(unadjusted) 
+ 1.42 (0.50;2.34) 0.0013 - 1.50 (-2.73;-0.26) 0.0089 
Larsen score (adjusted for the shared epitope) - 1.88 (-3.15;-0.60) 0.0020 
Larsen score (adjusted for treatment) - 1.50 (-2.75;-0.25) 0.0094 
Modified Larsen score + 1.51 (0.66;2.35) 0.00024 - 1.65 (-2.80;-0.50) 0.0025 










Table 2. Association of FOXO3A and the shared epitope with non-radiological 
measures of disease outcome or activity  
For outcome measures modelled with quantile regression, the following is reported: 
Odds ratio (e raised to the power of the observed coefficient), normal-based 95% 
Confidence Interval (CI), Bootstrap one-tailed p-value.  
For CRP (modelled with ZINB) results from the categorical (inflate) part of the model 
are reported: Odds ratio (e raised to the power of the observed coefficient for being 
non-zero), 95% Confidence Interval (CI), robust p-value.  
HAQ: Health Assessment Questionnaire. DAS28: Disease Activity Score based on 
28 joints (SJC, TJC, CRP). SJC: Swollen Joint Count. TJC: Tender Joint Count. 





Shared epitope FOXO3A (rs12212067) 
 
Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
HAQ score 1.15   (1.06-1.25) 0.00019 0.94   (0.84-0.96) 0.11 
DAS28 1.19  (1.02-1.38) 0.013 0.78   (0.66-0.93) 0.0029 
SJC 1.22   (1.05-1.42) 0.0052 0.86   (0.73-1.03) 0.048 
TJC 1.08   (0.80-1.45) 0.3 0.84   (0.59-1.20) 0.17 
CRP 1.38   (1.09-1.72) 0.0032 0.74   (0.56-0.97) 0.016 
Table 3. Adjustement for and stratification by anti-CCP status. 
 
Shared epitope FOXO3A (rs12212067) 
 Anti-CCP positive Anti-CCP negative Adjusted for anti-CCP 
status 























+ 1.05  
(-1.45;+ 3.54) 
0.205 
+ 0.23  
(-0.61;+1.07) 
0.295 































The association studies presented in Table 1 for the Larsen score in RA and in Table 2 for DAS28 in inflammatory polyarthritis 
have been performed again either by adjusting for anticyclic citrullinated peptide (anti-CCP) antibody status (column 3 and 6) or by 
stratifying by anti-CCP status, i.e. the analysis was restricted exclusively to anti-CCP positive (column 1 and 4) or anti-CCP 
negative disease (column 2 and 5). Since the effect of the SE is almost completely mediated by anti-CCP, it disappears completely. 
However, the adjustment has no major influence on the association of FOXO3A rs12212067. Stratification decreases sample size 
and therefore power, which is likely to explain the lack of significance in the smaller anti-CCP positive group for the Larsen score. 
Overall, these results indicate that the biological pathways mediating the effect of the SE and FOXO3A are different. CI, Confidence 
Interval; p-values are one-tailed; dimensions and interpretation of effect sizes are explained in the legend of Table 1 and 2.   
DISCUSSION 
FOXO3 is a transcription factor that has been linked to the regulation of immune 
responses using systems biology[26] and knockout mouse models[27] and which 
has been shown to be overexpressed in blood and synovial leukocytes in RA.[28] 
We have previously reported that minor allele carriage at rs12212067, a non-coding 
SNP in FOXO3, is associated with a milder course of several TNFα-driven diseases, 
including RA, and have described a FOXO3-dependent pathway that is regulated by 
this genetic variant and which – via TGFβ1 induction – modulates inflammatory 
responses in monocytes.[10] This genetic association, however, was not detected in 
a follow-up study by van Steenbergen and colleagues, which included 5 smaller RA 
cohorts and a mixture of prospective and retrospective patients, and of early and 
established RA.[13] A non-significant trend to a protective effect of the minor allele at 
rs12212067 – consistent with our results – was, however, observed in their meta-
analysis, and particularly in the cohorts of early RA patients for whom multiple sets of 
radiographs were available.[13] Nonetheless, given these apparently contradictory 
reports,[10, 13] we sought to better understand what role, if any, FOXO3 plays in 
influencing disease course in RA.  
We first sought to establish whether a contribution of FOXO3 to the course of 
immune-mediated arthritis was biologically plausible, given that genetic associations 
alone do not establish biological relevance to disease. Indeed, even though we had 
previously identified an inflammatory pathway that is modulated by genetic variation 
at rs12212067, this does not definitively prove that any association with radiographic 
outcome in RA is due to effects on inflammation. We therefore examined the role of 
Foxo3 in immune-mediated arthritis in vivo using an animal model that has 
previously been extensively and successfully used to delineate pathogenic 
mechanisms in RA and test new therapies.[18] Based on the results of these 
experiments, we then used detailed phenotypic data from the largest cohort of early 
RA patients worldwide to assess for associations with other measures of 
inflammation and disease severity. We demonstrate that altered Foxo3 function does 
modulate the severity of autoimmune arthritis in vivo, and identify genetic 
associations with several other indices of inflammation and disease severity in RA 
patients. Together, these results strengthen the previously reported association of 
FOXO3 with outcome in RA. Moreover, these data suggest that rather than having a 
direct effect on bone, the contribution of FOXO3 to outcome in RA is likely to be by 
modulating inflammation (e.g. CRP) and disease activity (e.g. SJC, DAS28) which 
would then lead to differences in radiographic outcome (e.g. Larsen score, erosions). 
However, the effect of FOXO3 is independent of the SE and of the presence of anti-
CCP antibodies, which is consistent with two different mechanisms of action for 
these two different genetic markers. Importantly, the size of the effects on 
radiographic damage and DAS28, while statistically significant, are unlikely to be 
clinically useful in isolation (e.g. for applications such as predicting disease 
outcome), as the proportion of the phenotypic variance explained by the FOXO3 
SNP only is below 0.1% (0.07% for Larsen score and 0.09% for DAS28). This does 
not preclude, however, the inclusion of this SNP in a model that could incorporate 
several predictive factors (e.g. genetic, demographic, clinical and environmental). In 
the future, such a model could comprise a set of several hundreds of SNP of small 
effect sizes. With current technological advances and the commercialization of high 
throughput (chip-based) genotyping platforms for clinical applications, this approach 
will become a realistic diagnostic/prognostic option. Moreover, irrespective of the 
utility of this SNP for predicting disease course, by studying the functional effects of 
such associations, it may be possible to uncover previously unappreciated pathways 
that are amenable to pharmacological intervention, and so develop better 
treatments. Such a discrepancy between the effect size of an associated SNP and 
the therapeutic potential of targeting the underlying biology has already been 
observed in cardiovascular medicine, where genetic variants in HMGCR are 
associated with very modest changes in serum LDL (~5%, [29]) but the protein 
product of this gene, HMG CoA reductase, is the pharmacological target of the most 
effective drug treatment for hypercholesterolaemia[30] (statins). An important caveat, 
however, is that the associations of rs12212067 with the indices of RA severity 
described herein have not yet been replicated, even though these indices were 
selected because of the a priori hypothesis that minor allele carriage at rs12212067 
would associate with milder disease. Accordingly, these associations should be 
examined further in larger and appropriately-powered replications cohorts.   
Since the advent of GWAS, it has been commonplace for the reporting of new 
genetic associations to be followed by several smaller, and often underpowered, 
studies that attempt to replicate the reported associations, with varying degrees of 
success. Here, we confirm that FOXO3 plays an important role in the determining 
the course of immune-mediated arthritis in vivo and detect associations between 
genotype at rs12212067 and a range of RA severity measures. It is therefore 
important to consider why this association was not detected in a previous follow-up 
study.[13] One possibility is that the genetics and biology of disease outcome are 
genuinely different between the populations studied. However, given that both study 
populations were derived from the same ethnic ancestry, this seems less likely and 
other possibilities need to be considered. An alternative explanation is that the 
relatively small size of the individual cohorts in the replication study[13] may have 
limited their power to detect any effect. This is likely to have been further hampered 
by the considerable inter-cohort heterogeneity, both in terms of clinical phenotype 
(i.e. early vs. established RA) but also in terms of the available radiographic data. 
For example, in 50% of the cases only a single set of radiographs were available. 
This meant that progression could not be assessed in a uniform way across all 
cohorts, being directly measured in some, and extrapolated based on assumed 
linear disease progression in others, an assumption that is unlikely to be valid for 
most patients.[31] Standardised phenotype definitions are critical for multi-centre 
studies to prevent introducing site-based bias(es) and to ensure that the final meta-
analysis is interpretable.[32] Accordingly, we would contend that rather than 
disproving a role for FOXO3 in the outcome of RA, this negative study actually re-
emphasises the need for consistent definitions in replication studies, as others have 
highlighted.[32]  
Collectively, therefore, our data provide further support for the observation that a 
SNP, which has not been associated with susceptibility to RA (MAF in 3879 UK RA 
cases: 0.103; MAF in 8428 controls: 0.104; OR: 0.994 (95% CI: 0.910-1.085), P = 
0.89[2]) is associated with disease outcome. This highlights possible new directions 
for candidate gene or pathway-based studies in complex disease genetics, and 
suggests that by identifying other genetic variants that associate with outcome, it 
may ultimately be possible to develop prognostic tests that have sufficient 
performance to guide treatment decisions. As with studies of disease susceptibility, 
however, such work will probably require large sample sizes and meta-analyses to 
confirm associations at genome-wide significance levels. International consortia will 
undoubtedly be critical in achieving this goal. 
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Figure 1. Loss of Foxo3 activity predisposes to more severe arthritis in a 
mouse model 
(A-D) Collagen-induced arthritis was induced in littermate Foxo3+/+, Foxo3+/- and 
Foxo3-/- mice. Results representative of two experiments each with a minimum of 6 
mice per group. Data are represented as Mean ± SEM. Wilcoxon signed-rank test 
unless indicated.  
(A) Disease severity scores (sum of limb scores where each limb is scored from 0-4, 
per Brand et al. 2007). Two-way ANOVA. 
(B) Light microscopy of H&E stained joint sections from Foxo3-/- and Foxo3+/+ mice 
demonstrating loss of joint space and synovial expansion. Day 14.  
(C) Anti-collagen antibody titres (day 14). AU, Arbitrary Units. 
(D) Serum IL-6 (day 14) 
 
 
